A number of other research firms have also recently weighed in on XLRN. Barclays set a $24.00 price target on Orion Engineered Carbons and gave the company a hold rating in a report on Friday, May 3rd. ValuEngine cut Acceleron Pharma from a strong-buy rating to a buy rating in a report on Thursday, April 18th. Cowen reaffirmed a buy rating on shares of Ovid Therapeutics in a report on Sunday, May 12th. Citigroup set a $27.00 price target on PhaseBio Pharmaceuticals and gave the company a buy rating in a report on Friday, May 24th. Finally, Piper Jaffray Companies dropped their price target on Motus GI from $8.00 to $6.00 in a report on Friday, May 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and seven have given a buy rating to the company. The company has an average rating of Hold and an average target price of $60.63.
Acceleron Pharma stock opened at $42.00 on Friday. The company has a debt-to-equity ratio of 0.05, a current ratio of 19.26 and a quick ratio of 19.26. The company has a market cap of $2.23 billion, a P/E ratio of -16.22 and a beta of 1.21. Acceleron Pharma has a one year low of $37.01 and a one year high of $59.59. The stock’s 50 day moving average is $40.54.
Acceleron Pharma (NASDAQ:XLRN) last posted its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.07). The company had revenue of $2.78 million for the quarter, compared to the consensus estimate of $3.67 million. Acceleron Pharma had a negative return on equity of 35.94% and a negative net margin of 965.39%. Acceleron Pharma’s quarterly revenue was down 13.9% compared to the same quarter last year. During the same quarter last year, the business earned ($0.58) EPS. On average, sell-side analysts anticipate that Acceleron Pharma will post -2.44 EPS for the current year.
In other news, Director Jean George sold 25,688 shares of Acceleron Pharma stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $39.16, for a total value of $1,005,942.08. Following the completion of the sale, the director now directly owns 23,750 shares of the company’s stock, valued at approximately $930,050. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Joseph S. Zakrzewski bought 5,000 shares of the stock in a transaction dated Friday, June 14th. The stock was purchased at an average cost of $38.05 per share, with a total value of $190,250.00. Following the completion of the purchase, the director now directly owns 12,750 shares in the company, valued at approximately $485,137.50. The disclosure for this purchase can be found here. Insiders have sold a total of 63,726 shares of company stock valued at $2,519,969 over the last ninety days. Insiders own 2.50% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in XLRN. Clarfeld Financial Advisors LLC acquired a new stake in shares of Acceleron Pharma in the 4th quarter valued at $44,000. Quadrant Capital Group LLC acquired a new stake in shares of Acceleron Pharma in the 1st quarter valued at $46,000. Citizens Financial Group Inc RI acquired a new stake in shares of Acceleron Pharma in the 1st quarter valued at $47,000. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Acceleron Pharma by 13.7% in the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,958 shares of the biopharmaceutical company’s stock valued at $138,000 after buying an additional 356 shares during the period. Finally, Amundi Pioneer Asset Management Inc. acquired a new stake in shares of Acceleron Pharma in the 4th quarter valued at $157,000. 92.54% of the stock is owned by institutional investors.
Acceleron Pharma Company Profile
Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.
Featured Article: What defines an oversold asset?
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.